Respiratory Syncytial Virus (RSV) News and Research

RSS

Respiratory syncytial virus (RSV) causes mild, cold-like symptoms in adults and older children. However, it can cause serious problems in young babies, including pneumonia and severe breathing problems. In rare cases it can lead to death. Premature babies and those with other health problems have the highest risk. A child with RSV may have a fever, stuffy nose, cough and trouble breathing. Tests can tell if your child has the virus.

February is again peak time for influenza across the nation

If you thought the regular seasonal flu has been late making its annual appearance, you might be surprised to learn that based on recent history, it's right on time.

15 Feb 2011

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.

23 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

GenVec, Inc. announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH).

7 Dec 2010

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

1 Dec 2010

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Acute respiratory infections (ARIs) - such as influenza, pneumonia and respiratory syncytial virus (RSV) - cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).

10 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus (RSV) infections.

29 Sep 2010

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Novavax, Inc. reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus, showed the vaccine to be safe and well-tolerated at all doses tested. Novavax's vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus. There is currently no approved vaccine to prevent RSV infection.

13 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Researchers at the University of Warwick, and the Kenya Medical Research Institute, Kilifi, Kenya, have found that respiratory syncytial virus (RSV) appears to be the predominant virus detected among infants and children hospitalized in Kenya with severe pneumonia, according to a study in the May 26 issue of JAMA. The contribution to this severe disease by an individual pathogen stresses the need for effective infant vaccination.

28 May 2010

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

Among infants and children hospitalized in Kenya with severe pneumonia, respiratory syncytial virus appears to be the predominant virus detected, according to a study in the May 26 issue of JAMA.

26 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010